NCT03360097

Brief Summary

This study evaluates which transfer strategy will result in a higher probability of pregnancy in patients whose single best day 5 embryo resulting from an IVF cycle is classified as expansion grade \<4 by Gardner and Schoolcraft classification. All cycles will be cultured to day 6 and half the patients will undergo a fresh embryo transfer and the other half a frozen embryo transfer.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2017

Completed
17 days until next milestone

Study Start

First participant enrolled

December 1, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 2, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2018

Completed
Last Updated

June 1, 2018

Status Verified

May 1, 2018

Enrollment Period

6 months

First QC Date

November 14, 2017

Last Update Submit

May 30, 2018

Conditions

Keywords

In vitro FertilizationSlow Developing BlastocystFresh Embryo TransferFrozen Embryo TransferLive Birth Rate

Outcome Measures

Primary Outcomes (1)

  • Clinical Pregnancy Rate

    Proportion of patients with the presence of a gestational sac seen by transvaginal ultrasonography 20 days after the embryo transfer

    20 days after date of embryo transfer

Secondary Outcomes (4)

  • Biochemical Pregnancy Rate

    9 days after date of embryo transfer

  • Live Birth Rate

    24 weeks after the embryo transfer

  • Miscarriage Rate

    14 weeks after the embryo transfer

  • Cryopreservation-thaw rate

    1 day after the thawing procedure

Study Arms (2)

Fresh ET

NO INTERVENTION

The best available embryo is at expansion grade \<4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.

Frozen Embryo Transfer

EXPERIMENTAL

The best available embryo is at expansion grade \<4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.

Procedure: Frozen Embryo Transfer

Interventions

Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle

Frozen Embryo Transfer

Eligibility Criteria

Age18 Years - 44 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • All IVF cycles undergoing autologous fresh blastocyst embryo transfer
  • All IVF cycles in which the best available embryo for transfer is at expansion grade \<4
  • All ages

You may not qualify if:

  • Ovum Donation cycles
  • Preimplantation genetic testing cycles

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Universitari Dexeus

Barcelona, 08022, Spain

Location

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Officials

  • Jorge Rodriguez-Purata, MD

    Fundacion Dexeus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: All participants will be randomized by an intention to treat approach. Randomization at the blastocyst stage is chosen to avoid cycle cancellation if randomized earlier. All components of the IVF/ICSI cycle including stimulation medications, monitoring protocols, etc. will be at the discretion of the participant's primary physician; while this information will be documented it will not constitute criteria for enrolment. The group allocation will take place the day of the embryo transfer. The clinician will randomize all included patients into one of the two study groups using an open computer-generated list. An interim analysis is planned and sample size will be plan accordingly, under the Pocok method, including 2 stages, with p-value as boundary scale, calculated to have 80% power to detect a 20% difference with a reference proportion of 25% clinical pregnancy rate and a one-sided (upper) alpha of 0.025
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 14, 2017

First Posted

December 2, 2017

Study Start

December 1, 2017

Primary Completion

May 30, 2018

Study Completion

May 30, 2018

Last Updated

June 1, 2018

Record last verified: 2018-05

Data Sharing

IPD Sharing
Will share

all collected IPD

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
January 2020
Access Criteria
All

Locations